Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Hall Laurie J Trustee

Hall Laurie J Trustee grew its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,143 shares of the pharmaceutical company’s stock after acquiring an additional 383 shares during the period. Hall Laurie J Trustee’s holdings in Vertex Pharmaceuticals were worth $2,071,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of VRTX. Czech National Bank raised its position in Vertex Pharmaceuticals by 6.2% during the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after acquiring an additional 3,260 shares during the last quarter. Whalen Wealth Management Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth approximately $662,000. Creative Planning raised its position in shares of Vertex Pharmaceuticals by 5.3% during the 2nd quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock worth $37,084,000 after purchasing an additional 3,998 shares during the last quarter. Mizuho Securities USA LLC lifted its stake in Vertex Pharmaceuticals by 289.0% in the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after buying an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB grew its holdings in Vertex Pharmaceuticals by 19.4% during the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after buying an additional 55,739 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Canaccord Genuity Group upped their price objective on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research report on Wednesday, November 6th. JPMorgan Chase & Co. reduced their target price on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Barclays reduced their target price on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a research report on Friday, December 20th. Finally, William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Monday, January 13th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $422.00 on Monday. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average price is $440.94 and its two-hundred day moving average price is $466.09.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $3.67 EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.